M-F Hsueh1, M P Bolognesi2, S S Wellman3, V B Kraus4. 1. Duke Molecular Physiology Institute, Durham, NC, USA; Department. of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA. Electronic address: mingfeng.hsueh@duke.edu. 2. Department. of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA. Electronic address: michael.bolonesi@duke.edu. 3. Department. of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA. Electronic address: samuel.wellman@duke.edu. 4. Duke Molecular Physiology Institute, Durham, NC, USA; Division of Rheumatology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Electronic address: vbk@duke.edu.
Abstract
OBJECTIVE: To evaluate the anti-inflammatory effects of clinically relevant naproxen sodium (Nx) concentrations on human monocyte-derived macrophages in a controlled in vitro system and human primary synovial fluid (SF) cells. DESIGN: Using phorbol 12-myristate 13-acetate, THP-1 human monocytic cells were differentiated into mature monocyte-derived macrophages in vitro then treated with Nx pre- or post-activating an inflammatory response with lipopolysaccharide (LPS) and hyaluronan (HA) fragments (n = 8/group). Cell culture supernatants were assessed for NF-κB activity and prostaglandin E2 (PGE2), indicating cyclooxygenase enzyme activity. Under Duke IRB approval, primary human SF cells were collected at the time of knee joint replacement (n = 19 individuals) for osteoarthritis (OA), and cultured with LPS, HA and Nx; SF cells were characterized by polychromatic flow cytometry for cell surface markers and intracellular cytokines. RESULT: Compared to placebo treatment of THP-1 cells, low dose Nx (corresponding 27.5-440 mg/L orally) added both pre- and post-activation with LPS/HA, significantly reduced NF-κB activity and PGE2: mean reduction to 73%, 61%, 17% and 10% of placebo, respectively. LPS/HA treatment of primary OA SF cells significantly increased the number of IL-1β producing primary monocytes and macrophages, and by 24 h the overall production of secreted cytokines (IL-1β, IL-6, IL8, and TNF-α). Low dose Nx reduced the percentage of IL-1β producing primary monocytes and macrophages. CONCLUSION: LPS/HA induced inflammation of THP-1 monocytic and primary human SF cells. Low dose Nx both prevented and reduced inflammatory responses of a human monocytic cell line and reduced IL-1β production by primary human SF monocytes and macrophages.
OBJECTIVE: To evaluate the anti-inflammatory effects of clinically relevant naproxen sodium (Nx) concentrations on human monocyte-derived macrophages in a controlled in vitro system and human primary synovial fluid (SF) cells. DESIGN: Using phorbol 12-myristate 13-acetate, THP-1human monocytic cells were differentiated into mature monocyte-derived macrophages in vitro then treated with Nx pre- or post-activating an inflammatory response with lipopolysaccharide (LPS) and hyaluronan (HA) fragments (n = 8/group). Cell culture supernatants were assessed for NF-κB activity and prostaglandin E2 (PGE2), indicating cyclooxygenase enzyme activity. Under Duke IRB approval, primary human SF cells were collected at the time of knee joint replacement (n = 19 individuals) for osteoarthritis (OA), and cultured with LPS, HA and Nx; SF cells were characterized by polychromatic flow cytometry for cell surface markers and intracellular cytokines. RESULT: Compared to placebo treatment of THP-1 cells, low dose Nx (corresponding 27.5-440 mg/L orally) added both pre- and post-activation with LPS/HA, significantly reduced NF-κB activity and PGE2: mean reduction to 73%, 61%, 17% and 10% of placebo, respectively. LPS/HA treatment of primary OA SF cells significantly increased the number of IL-1β producing primary monocytes and macrophages, and by 24 h the overall production of secreted cytokines (IL-1β, IL-6, IL8, and TNF-α). Low dose Nx reduced the percentage of IL-1β producing primary monocytes and macrophages. CONCLUSION:LPS/HA induced inflammation of THP-1 monocytic and primary human SF cells. Low dose Nx both prevented and reduced inflammatory responses of a human monocytic cell line and reduced IL-1β production by primary human SF monocytes and macrophages.
Authors: Alessio Bricca; André Struglics; Staffan Larsson; Martijn Steultjens; Carsten B Juhl; Ewa M Roos Journal: Arthritis Care Res (Hoboken) Date: 2019-11 Impact factor: 4.794
Authors: Jan Bondeson; Sarah Lauder; Shane Wainwright; Nick Amos; Amy Evans; Clare Hughes; Marc Feldmann; Bruce Caterson Journal: J Rheumatol Date: 2007-01-15 Impact factor: 4.666
Authors: Tony Ashton; Ian S Young; Gareth W Davison; Christopher C Rowlands; Jane McEneny; Catherine Van Blerk; Eleri Jones; John R Peters; Simon K Jackson Journal: Free Radic Biol Med Date: 2003-08-01 Impact factor: 7.376
Authors: Pérola Grinberg Plapler; Morton Aaron Scheinberg; Christina da Cunha Ecclissato; Monalisa Fernanda Bocchi de Oliveira; Roberto Bleuel Amazonas Journal: Drug Des Devel Ther Date: 2016-06-17 Impact factor: 4.162